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Studies have demonstrated that healthcare personnel (HCP) have concerns about 
the potential side effects of trivalent inactivate influenza vaccine (IIV3).1-3 A recent 
meta-analysis of reasons HCP refuse IIV3 indicates the strongest predictors of 
vaccine acceptance are belief that the vaccine is safe and belief the vaccine does 
not cause the disease it is meant to prevent.1 
 
Timely vaccine safety information for each new seasonal IIV3 vaccine can be used 
to reassure HCP. In addition, the ability to provide real-time safety profiling of new 
vaccines should form part of emergency preparedness planning, for example in the 
case of rapid development and rollout of vaccines in a pandemic. 
 
Despite ready access to vaccines and concerted efforts to promote uptake, influenza 
vaccination coverage among HCP in Australia has historically been low, ranging 
from 18-66%.5 In a review of 32 studies from the United States (13), Canada (5), 
Europe (11) and others (3), Hofmann et al. found influenza vaccine coverage of less 
than 50% in HCP in the majority (26/32, 81%) of these studies.6 
 
In 2014, the Western Australian Department of Health (“WA Health”) developed the 
Follow-up and Active Surveillance of Trivalent Influenza Vaccine in HCP 
(FASTHealth) program.  FASTHealth is an SMS-based, active influenza vaccine 
safety monitoring program intended to be implemented at the start of each season’s 







































































WA Health provides free IIV3 for staff working in government health facilities and 
maintains a centralised record keeping system for recording HCP influenza 
immunisation. In 2014, HCP were asked at the time of vaccination to participate in 
the FASTHealth program to monitor adverse events following immunisation (AEFIs). 
HCP who consented and provided a mobile phone number were sent a text 
message (or ‘SMS’) seven days after vaccination querying whether they had 
experienced any ‘reaction, fever or illness’ following vaccination.   
 
A second SMS was sent 24 hours later to anyone who did not reply to the first 
message. HCP who responded “Yes” to either message were sent a link to a mobile 
phone survey to record the details of their AEFI. Those who opted not to complete 
the smart phone survey and those who did not reply to either SMS were telephoned 
to ascertain specifics of any AEFI via a standardised interview with a research nurse.  
Both surveys were identical in content and asked whether the participant 
experienced fever, headache, fatigue, vomiting, rash, rigors, convulsions or swelling 
or pain at the injection site. Other reported potential side-effects were recorded 
verbatim/as written.  
 
Results  
Between 19 March and 20 May 2014, 1,624 HCP, including medical, administration 
and support staff, were sent an SMS soliciting whether they experienced an AEFI. 
The majority were female (81%) and between 18-44 years of age (56%); 835 HCP 
received intradermal IIV3 (Intanza®: 51.4%) and 789 received an intramuscular IIV3 




































































Of those who were sent an SMS message, 1,432 (88%) replied.  A total of 239 
(17%) of the respondents replied affirmatively that they had experienced one or more 
reactions to the vaccine.  Of those reporting reactions, 184 (77%) provided details 
regarding the AEFI: 66 via the mobile phone survey and 118 by telephone. The 
remaining 55 HCP were lost to follow-up.  
 
Among the 192 HCP who did not reply to the SMS, 65 (34%) were subsequently 
reached by telephone and 20 (31%) of these reported an event. In aggregate, 1,442 
HCP provided complete information regarding the occurrence of AEFI, of which 204 
(14.1% [95% CI 12.2-16.1%]) reported at least one reaction (Figure).  
 
Figure. Responses to the FASTHealth program 19 March – 20 May 2014. 
 
No severe adverse events were reported. A total of 137 HCP reported at least one 
systemic symptom, most commonly fatigue (3.8% [95% CI 2.8-4.8%]), headache 
(3.7% [95% CI 2.7-4.7%]) or respiratory symptoms (3.7% [95% CI 2.7-4.7%]). 115 
HCP reported redness, pain or swelling at the injection site (8.0% [95% CI 6.5-




Use of SMS technology in the FASTHealth program allowed rapid, active 
surveillance of the safety of IIV3 offered free to HCP as part of the annual influenza 
program. Consistent with previous vaccine safety investigations of seasonal IIV3 in 




































































As the antigenic components of the influenza vaccine can change season-to-season 
and safety profiles from previous seasons’ formulations may not be applicable to 
current vaccines, it is particularly important to monitor the safety of IIV3 each year.  
Our findings demonstrate the feasibility of implementing a timely, resource-
conserving, vaccine safety monitoring system among HCP each year during 
influenza vaccination season.   
 
Previous methods to capture AEFI following IIV3 in HCP mainly include self-report 
paper questionnaires, which require significantly more time to capture, record and 
analyse the data.4,7,8 Smartphone penetration in Australia was reported at 65% in 
2013, making it a suitable market for the use of such technology.8 In the same 
survey, smartphone use is reportedly less common in other countries such as the 
United Kingdom (62%) and the United States (56%), however overall there is 
increasing smartphone penetration globally, and in future the use of this technology 
has applications any time a new vaccine is introduced.9 
 
The information obtained can be used to reassure HCP regarding the reactogenicity 
of the vaccine, and potentially used to improve uptake among HCP. Future studies 
should investigate communication strategies for informing HCP about the safety of 
IIV3. Considering the potential to prevent disease in HCP, their families and their 
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